FLAG Therapeutics has an exceptionally strong intellectual property (IP) portfolio surrounding its three propriety drug discovery platforms. In addition to the protection offered by its IP estate, which includes both composition of matter (CoM) and method of use (MoU) patents, many of the indications the company is seeking to address have been granted, or are eligible for, specific regulatory designations such as Orphan Drug Designation (ODD) and Rare Pediatric Drug Designation (RPDD). These regulatory designations hold the potential to provide FLAG with additional advantages, such as extended market exclusivity, tax incentives and waived regulatory filing fees.

To date, FLAG’s global IP portfolio includes over 100 issued patents and over 30 pending applications. Pursuant to an exclusive worldwide licensing agreement between FLAG Therapeutics and Duquesne University (DU), all new discoveries and improvements derived from these three platforms belong exclusively to FLAG. Additionally, FLAG maintains the right to sublicense the technologies as well.